• the use of animal models for determination of antithrombotic drug efficacy
• antithrombotic therapy as a key component of cardiovascular disease management
• the management of thromboembolic events in children and pregnant women

New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.

Contents

1. Overview
   1. Overview of Hemostasis and Fibrinolysis
   2. A Survey of Animal Models to Develop Novel Antithrombotic Agents
   3. Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents

2. New Heparins, Thrombin Inhibitors, and Other New Agents
   4. Overview of New Anticoagulant Drugs
   5. Low-Molecular-Weight Heparins in Acute Coronary Syndromes
   6. Low-Molecular-Weight Heparin Use in Pregnancy
   7. Antithrombotic Therapy and Cancer
   8. Thrombosis Prophylaxis with Low-Molecular-Weight Heparin in Medical Patients
   9. Low-Molecular-Weight Heparins in Prevention and Treatment of Venous Thromboembolism
   10. Low-Molecular-Weight Heparin in the Pediatric Population
   11. New Indications for Low-Molecular-Weight Heparins
   12. Clinical Use of Argatroban
   13. Hirudin for Acute Coronary Syndromes
   14. Clinical Development of Bivalirudin
   15. Development of a Synthetic Heparin Pentasaccharide as an Antithrombotic Agent
   16. Oral-Direct Thrombin Inhibitors
   17. Orally Active Heparin
   18. Tissue Factor Pathway Inhibitor: Potential Implications in the Treatment of Cardiovascular Disorders
   19. Modulation of the Protein C Pathway as a Therapy for Thrombosis
   20. Soluble Thrombomodulin

3. New Antiplatelet Agents
   21. Overview: Antiplatelet Therapy
   22. Abciximab
   23. Eptifibatide: A Potent Inhibitor of the Platelet Receptor Integrin, Glycoprotein IIb/IIIa
   24. Tirofiban: A Paradigm for “Small-Molecule” Glycoprotein IIb/IIIa Receptor Antagonists?
   25. Procoagulant Activities of Glycoprotein IIb/IIIa Receptor Blockers
   26. Inhibitors of von Willebrand Factor Binding to Platelet Glycoprotein Ib
   27. Thienopyridines: Ticlopidine and Clopidogrel
   28. Oral Antiplatelet Therapies Beyond Aspirin and Thienopyridines

4. New Thrombolytic Agents
   29. Overview of New Therapeutic Agents
   30. Clinical and Preclinical Profile of the Novel Recombinant Plasminogen Activator Reteplase
   31. Tenectaplase: Biochemistry, Pharmacology, and Clinical Experience
   32. Lanoteplase
   33. Monteplase: Pharmacological and Clinical Experience
   34. Pharmacological Action of and Clinical Experience with Pamiteplase, a Novel, Modified, Tissue-Type Plasminogen Activator
   35. Recombinant, Glycosylated Prourokinase: Preclinical and Clinical Studies
   36. A Mutant Form of Prourokinase That Spares Hemostatic Fibrin
   37. Recombinant Staphylokinase for Thrombolytic Therapy
   38. Desmodus rotundus (Vampire Bat) Plasminogen Activator DSPAa1: A Superior Thrombolytic Created by Evolution
   39. Alfimeprase
   40. In Vitro and In Vivo Models to Investigate Clot Lysis and Thrombolysis
   41. Thrombolysis and Ultrasound

Epilogue: The Management of Thrombotic and Cardiovascular Disorders in the 21st Century
Index